Rare Disease Treatments to Be Listed Within 100 Days… Five New Drugs Selected as First Recipients
Published
Five new drugs have been selected as the first targets of a pilot program to add rare disease treatments to the national health insurance list within 100 days. Patients with rare diseases have shown great interest in the program, as they cannot begin treatment until their medications are covered by insurance.
The program is funded by the National Health Insurance budget. By streamlining the process of adding new drugs to the insurance list, its goal is to enable patients to access the medications they need more quickly.
Currently, there are 49 pilot programs funded by the National Health Insurance budget. Cumulatively, more than 9 trillion won has been invested in these programs so far.
However, it has been found that 78.1% of the total funding was spent on programs that have never undergone a performance evaluation. This shows that there is a lack of procedures to verify what actual effects the pilot programs have had.
Whether this rare disease treatment program actually benefits patients, and how the National Health Insurance budget will be evaluated and managed, are expected to be important challenges going forward.
Sources: 코리아헬스로그
More South Korea news
- Digital TVET master's program launches in South Korea
- Gyeongbuk health group donates 100 boxes of grapes to children
- US Big Tech Pursues Multi-Trillion Won Investments in South Korean Data Centers Amid Uncertainty
- KB Insurance to Hold Open Recruitment for New Employees in Second Half of 2026
- Kolmar Korea Wins CES Beauty Tech Best Innovation Award for Second Straight Year, Setting World First
- China Closes In on Korea's Core LNG Carrier Market, Expanding from Mega-Vessels to Equipment
- China's Rapid Technological Development: South Korea Must Change Its Regulations and Labor System
- Ambassador Michelle Steel: American Companies Operating in Korea Should Compete in a Fair Environment